Evidence map›Paper›PMID 32480200›Full record

ArticleJournal of pharmaceutical and biomedical analysis2020

Forced degradation studies of medroxyprogesterone acetate injectable suspensions (150 mg/ml) with implementation of HPLC, mass spectrometry, and QSAR techniques.

David Jenkins, Christopher L Harmon, Xiao Jia, Allen Kesselring, Danielle Hatcher, Katie Grayson, Jennifer Ayres

Open access · hybridAbstract read
In one paragraph

Article in Journal of pharmaceutical and biomedical analysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

David JenkinsProduct Quality and Compliance, FHI 360, 2810 Meridian Parkway, Suite 160, Durham, NC 27713, USA. Electronic address: DJenkins@fhi360.org.
Christopher L HarmonProduct Development and Introduction, FHI 360, 359 Blackwell Street, Suite 200, Durham, NC 27701, USA. Electronic address: CHarmon@fhi360.org.
Xiao JiaEKG Life Science Solutions, 4633 World Parkway Circle, St. Louis, MO 63134, USA. Electronic address: xjia@ekglabs.com.
Allen KesselringEKG Life Science Solutions, 4633 World Parkway Circle, St. Louis, MO 63134, USA. Electronic address: akesselring@ekglabs.com.
Danielle HatcherEKG Life Science Solutions, 4633 World Parkway Circle, St. Louis, MO 63134, USA. Electronic address: dhatcher@ekglabs.com.
Katie GraysonEKG Life Science Solutions, 4633 World Parkway Circle, St. Louis, MO 63134, USA. Electronic address: kgrayson@ekglabs.com.
Jennifer AyresProduct Development and Introduction, FHI 360, 359 Blackwell Street, Suite 200, Durham, NC 27701, USA. Electronic address: jayres@fhi360.org.
Family Health International 360 · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Medroxyprogesterone acetate (MPA) injectable products are a key commodity for reproductive health and are available in the global market from a variety of manufacturing sources. Depending on the climatic zone conditions of the destination country for product use, MPA injectables are at risk of exposure to adverse transport and storage conditions. Analytical methods are available that quantify impurity levels in MPA and MPA injectable products, but minimal information is publicly available on the source of impurity and degradation product generation or the safety risk of these compounds. Forced degradation studies were conducted on MPA and MPA injectables to gain a better understanding of potential sources of impurities and degradation products. Furthermore, QSAR analysis was conducted to assess the toxicity risk of known impurities. More impurities were generated under acidic, basic, light, and oxidative forced degradation conditions relative to thermal degradation, however thermal exposure is the most likely adverse condition to be experienced by these products. Even if impurities are present in MPA injectables, QSAR analysis found that known impurities for MPA are apparently no more of a safety risk than MPA.

Indexed as

Chromatography, High Pressure LiquidContraceptive Agents, HormonalDrug ContaminationDrug StabilityDrug StorageInjectionsMass SpectrometryMedroxyprogesterone AcetateQuantitative Structure-Activity RelationshipSuspensionsContraceptive Agents, HormonalMedroxyprogesterone AcetateSuspensionsForced degradationHPLC-MS/MSMedroxyprogesterone acetateQuantitative structure activity relationshipsToxicity risk

Identifiers

PMID32480200
PMCPMC7322552
OpenAlexW3021759915

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.